Literature DB >> 31768361

Conjunctival Melanoma in Childhood and Adolescence: A Systematic Review.

Ben W R Balzer1,2, Svetlana Cherepanoff3,4, Anthony M Joshua3, Michael Giblin5, Robert Max Conway4, Antoinette C Anazodo1,2,6,7.   

Abstract

BACKGROUND: Conjunctival melanoma is rare in adults and rarer in children. We systematically reviewed the presentation, diagnostic and management strategies as well as outcomes for conjunctival melanoma in children and adolescents.
METHODS: The following databases were searched: Medline, Embase, Web of Science and Scopus for cases of conjunctival melanoma occurring in children and adolescents < 18 years of age.
RESULTS: Seventeen studies with 32 patients (18 males) were identified. The median age at presentation was 11 years (range 4-18 years). Most patients were white. Most patients presented with a conjunctival mass or naevus with a recent history of growth or change. Excision biopsy provided diagnosis and management for all cases. Adjuvant chemotherapy and radiotherapy were also used. One patient had metastatic disease at diagnosis and 3 developed metastatic disease (range 1-10 months). Two patients died from disease and one was alive with metastatic disease. Two patients had disease recurrence. Outcomes were observed to be better where diagnosis was made earlier and "no-touch" excision biopsy was performed in an appropriate specialist setting.
CONCLUSIONS: Conjunctival melanoma occurs rarely in children and adolescents. Surgery is the mainstay of management. The prognosis is guarded in metastatic disease due to the small sample size and limited follow-up.
Copyright © 2019 by S. Karger AG, Basel.

Entities:  

Keywords:  Conjunctival melanoma; Paediatric oncology; Paediatric ophthalmology

Year:  2019        PMID: 31768361      PMCID: PMC6873081          DOI: 10.1159/000497813

Source DB:  PubMed          Journal:  Ocul Oncol Pathol        ISSN: 2296-4657


  38 in total

1.  Xeroderma pigmentosum observed in a Greenlander. Report of a case complicated by malignant melanoma of the conjunctiva.

Authors:  O A JENSEN
Journal:  Acta Ophthalmol (Copenh)       Date:  1962

2.  Conjunctival melanoma in children: a clinicopathologic study of 2 cases.

Authors:  Seymour Brownstein; Hamidreza Faraji; W Bruce Jackson; Ramon L Font
Journal:  Arch Ophthalmol       Date:  2006-08

3.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  Ann Intern Med       Date:  2009-07-20       Impact factor: 25.391

4.  Management of conjunctival malignant melanoma: a review and update.

Authors:  James R Wong; Afshan A Nanji; Anat Galor; Carol L Karp
Journal:  Expert Rev Ophthalmol       Date:  2014-06

5.  Nivolumab in the Treatment of Refractory Pediatric Hodgkin Lymphoma.

Authors:  Alexandra E Foran; Helen R Nadel; Anna F Lee; Kerry J Savage; Rebecca J Deyell
Journal:  J Pediatr Hematol Oncol       Date:  2017-07       Impact factor: 1.289

6.  Conjunctival melanoma: survival analysis in twenty-two Mexican patients.

Authors:  Rosa Angélica Salcedo-Hernández; Kuauhyama Luna-Ortiz; Leonardo Saúl Lino-Silva; Angel Herrera-Gómez; Verónica Villavicencio-Valencia; Miriam Tejeda-Rojas; José F Carrillo
Journal:  Arq Bras Oftalmol       Date:  2014 May-Jun       Impact factor: 0.872

7.  BRIM-P: A phase I, open-label, multicenter, dose-escalation study of vemurafenib in pediatric patients with surgically incurable, BRAF mutation-positive melanoma.

Authors:  Julia C Chisholm; Jozef Suvada; Ira J Dunkel; Michela Casanova; Weijiang Zhang; Natasha Ritchie; YounJeong Choi; Jane Park; Meghna Das Thakur; Stephen Simko; Nga Wan Rachel Tam; Andrea Ferrari
Journal:  Pediatr Blood Cancer       Date:  2018-01-19       Impact factor: 3.167

Review 8.  Malignant melanoma of the conjunctiva.

Authors:  Seymour Brownstein
Journal:  Cancer Control       Date:  2004 Sep-Oct       Impact factor: 3.302

9.  Experimental treatment of NRAS-mutated neurocutaneous melanocytosis with MEK162, a MEK-inhibitor.

Authors:  Heidi Vn Küsters-Vandevelde; Annelieke Ecab Willemsen; Patricia Jta Groenen; Benno Küsters; Martin Lammens; Pieter Wesseling; Melika Djafarihamedani; Jos Rijntjes; Hans Delye; Michel A Willemsen; Carla Ml van Herpen; Willeke Am Blokx
Journal:  Acta Neuropathol Commun       Date:  2014-04-08       Impact factor: 7.801

10.  BRAF, NRAS, and GNAQ Mutations in Conjunctival Melanocytic Nevi.

Authors:  Jasmine H Francis; Hans E Grossniklaus; Larissa A Habib; Brian Marr; David H Abramson; Klaus J Busam
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-01-01       Impact factor: 4.799

View more
  2 in total

Review 1.  Genetics of Ocular Melanoma: Insights into Genetics, Inheritance and Testing.

Authors:  Natasha M van Poppelen; Daniël P de Bruyn; Tolga Bicer; Rob Verdijk; Nicole Naus; Hanneke Mensink; Dion Paridaens; Annelies de Klein; Erwin Brosens; Emine Kiliҫ
Journal:  Int J Mol Sci       Date:  2020-12-30       Impact factor: 5.923

2.  Clinical and immunohistopathological study of conjunctival melanocytic lesions in pediatric and adolescent patients. A case series.

Authors:  Camelia Margareta Bogdănici; Claudia Florida Costea; Gabriela Florenţa Dumitrescu; Anca Sava; Delia Gabriela Ciobanu Apostol; Dragoş Viorel Scripcariu; Simona Delia Nicoară; Daniela Maria Tănase; Elena Corina Andriescu; Alexandru Cărăuleanu; Mihai Danciu; Silvia Cristina Sălăvăstru; Speranţa Schmitzer; Andrei Ionuţ Cucu; Irina Andreea Niagu
Journal:  Rom J Morphol Embryol       Date:  2021 Oct-Dec       Impact factor: 0.833

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.